{"DataElement":{"publicId":"3244788","version":"1","preferredName":"Person Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to a person's recovery from prior therapy as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3244787v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3244787","version":"1","preferredName":"Person Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person's recovery from prior therapy as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3244785v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3244785","version":"1","preferredName":"Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria","preferredDefinition":"One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.:Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C49498:C25629:C15697:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recovered from Adverse Event","conceptCode":"C49498","definition":"One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5C4AB2A-42ED-871F-E040-BB89AD433127","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"ONEDATA","dateModified":"2011-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5C4AB2A-42FE-871F-E040-BB89AD433127","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"},{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]},{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[{"name":"3244787v1.0:2018257v1.0","type":"USED_BY","context":"CTEP"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"3244787v1.0:2018257v1.0","type":"USED_BY","context":"COG"},{"name":"PtRcvrToxChxImXRTTxIND","type":"COG GDE Short Name","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"IE_IEORRES_CROS_RECOVERY","type":"OID, CCTG","context":"CCTG"},{"name":"PTRCVRTOXFXANTICATX","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Has patient fully recovered f","type":"Preferred Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study","url":null,"context":"CTEP"},{"name":"COG CRF Text_1","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior anti-cancer therapy prior to entering this study","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has patient received immunotherapy, chemotherapy, radiotherapy or experimental therapy within 28 days prior to first day of study drug dosing (6 weeks for nitrosoureas of mytomycin)?","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study?","url":null,"context":"COG"},{"name":"COG_CRF_TEXT_3","type":"Alternate Question Text","description":"Has patient recovered from any drug-related toxicity from any of the indicated agents","url":null,"context":"COG"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Has patient recovered to a grade 1 from all acute toxic effects of prior chemotherapies?","url":null,"context":"PBTC"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Have had chemotherapy or targeted small molecule therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.","url":null,"context":"CTEP"},{"name":"PBTC_Text3","type":"Alternate Question Text","description":"Has patient recovered to a less than or equal to grade 1 from all acute toxic effects of prior chemotherapies?","url":null,"context":"PBTC"},{"name":"PBTC_Text4","type":"Alternate Question Text","description":"Has patient recovered from clinically significant acute treatment related toxicities of prior therapies?  For those acute baseline adverse events attributable to prior therapy, recovery is defined as a toxicity Grade <= 2, using CTCAE v.4.0, unless otherwise specified in the Inclusion and Exclusion Criteria.","url":null,"context":"PBTC"},{"name":"COG_CRF_TEXT_4","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy?","url":null,"context":"COG"},{"name":"PBTC_Text5","type":"Alternate Question Text","description":"Has patient recovered to <= grade 1 from all acute toxic effects of prior chemotherapies?","url":null,"context":"PBTC"},{"name":"PBTC_Text6","type":"Alternate Question Text","description":"Has patient recovered to <= grade 1 from all acute toxic effects of prior chemotherapy, immunotherapy and/or radiotherapy prior to enrollment?","url":null,"context":"PBTC"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Adverse events (toxicity recovery)","url":null,"context":"Alliance"},{"name":"PBTC_Text7","type":"Alternate Question Text","description":"Has patient recovered to <= grade 1 from all acute toxic effects of prior chemotherapy, immunotherapy, or radiotherapy?","url":null,"context":"PBTC"},{"name":"ABTC 1501 Question Text","type":"Alternate Question Text","description":"Has patient recovered from severe toxicity of prior therapy? An interval of at least 12 weeks must have elapsed since the completion of radiation therapy or placement of Gliadel wafers, and at least 6 weeks must have elapsed from the last dose of temozolomide (TMZ).","url":null,"context":"ABTC"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior therapies prior to entering this study?","url":null,"context":"PBTC"},{"name":"COG_CRF_TEXT_5","type":"Alternate Question Text","description":"Has patient recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant or radiotherapy prior to entering this study","url":null,"context":"COG"},{"name":"ABTC 1302","type":"Alternate Question Text","description":"Has the patient recovered from severe toxicity of prior therapy? Â The following required intervals must have elapsed: at least 12 weeks from the completion of radiation, at least 6 weeks from a nitrosourea chemotherapy, at least 3 weeks from a non-nitrosourea chemotherapy, at least 4 weeks from any investigational (not FDA-approved) agents, at least 4 weeks from the last treatment with bevacizumab, and at least 2 weeks from administration of a non-cytotoxic, FDA-approved agent other than bevacizumab (e.g. hydroxychloroquine, etc.).","url":null,"context":"ABTC"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study?","url":null,"context":"COG"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"Has patient fully recovered from all acute toxic effects?","url":null,"context":"COG"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Is the patient eligible per toxicity recovery standards?","url":null,"context":"Alliance"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Has patient fully recovered  from the acute toxic effects of all prior anti-cancer therapy as defined in the protocol?","url":null,"context":"COG"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Does the patient have adverse events from prior anticancer therapy that have not resolved to Grade < 1 (except alopecia)","url":null,"context":"CTEP"},{"name":"PBTC_Text8","type":"Alternate Question Text","description":"Has the patient recovered from all acute effects of prior therapies (myelosuppressive chemotherapy, biological agent, monoclonal antibody, radiation therapy)?","url":null,"context":"PBTC"},{"name":"COG CRF TEXT 9","type":"Alternate Question Text","description":"Has patient fully recovered from all acute toxic effects of chemotherapy, immunotherapy, or radiotherapy prior to study enrollment?","url":null,"context":"COG"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Has the patient recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier?","url":null,"context":"CTEP"},{"name":"COG CRF TEXT 10","type":"Alternate Question Text","description":"Has patient completely recovered from all acute toxic effects of chemotherapy, immunotherapy, or radiotherapy prior to study enrollment?","url":null,"context":"COG"},{"name":"ABTC-1602 Question","type":"Alternate Question Text","description":"Has the patient recovered from severe toxicity of prior therapy?  The following required intervals must have elapsed: at least 12 weeks from the completion of radiation, at least 6 weeks from a nitrosourea chemotherapy or mitomycin C, at least 3 weeks from a non-nitrosourea chemotherapy, at least 4 weeks from any investigational (not FDA-approved) agents, at least 2 weeks from administration of a non-cytotoxic, FDA-approved agent other than bevacizumab (e.g. hydroxychloroquine, etc.), and at least 6 weeks from the last treatment with bevacizumab/VEGFR inhibitors.","url":null,"context":"ABTC"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"Has patient fully recovered from the acute non-hematologic toxic effects of all prior anti-cancer therapy as defined in the protocol?","url":null,"context":"COG"},{"name":"ABTC 1604/1603","type":"Alternate Question Text","description":"Has the patient recovered from severe toxicity of prior therapy? The following required intervals must have elapsed: at least 12 weeks from the completion of radiation, at least 6 weeks from a nitrosourea chemotherapy or mitomycin C, at least 3 weeks from a non-nitrosourea chemotherapy, at least 4 weeks from any investigational (not FDA-approved) agents, at least 2 weeks from administration of a non-cytotoxic, FDA-approved agent other than bevacizumab/VEGFR inhibitors (e.g. hydroxychloroquine, etc.), and at least 6 weeks from the last treatment with bevacizumab/VEGFR inhibitors.","url":null,"context":"CTEP"},{"name":"PBTC_Text9","type":"Alternate Question Text","description":"Has patient recovered to <= grade 1 from all acute toxic effects of prior radiotherapy?","url":null,"context":"PBTC"},{"name":"COG CRF TEXT 12","type":"Alternate Question Text","description":"Has patient fully recovered from the acute non-hematologic toxic effects of all prior anti-cancer therapy as defined in the protocol?","url":null,"context":"COG"},{"name":"PBTC_Text10","type":"Alternate Question Text","description":"Has the patient received prior therapy other than surgery and  fully recovered from the acute toxic effects of all  previous anti-cancer therapy prior to enrollment?","url":null,"context":"PBTC"},{"name":"COG CRF TEXT 13","type":"Alternate Question Text","description":"Has patient recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study?","url":null,"context":"COG"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Has the patient had prior treatment with an investigational EZH2 inhibitor?","url":null,"context":"CTEP"},{"name":"CRF Text11","type":"Alternate Question Text","description":"have these resolved to grade 1 or less?","url":null,"context":"Alliance"},{"name":"COG CRF TEXT 01","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior anti-cancer therapy prior to entering this study?","url":null,"context":"COG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, surgery, or radiotherapy prior to entering this study?","url":null,"context":"COG"},{"name":"CRF Text 40","type":"Alternate Question Text","description":"Does she agree to use two methods of contraception (hormonal or barrier method of birth control; abstinence)?","url":null,"context":"NRG"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Are all prior treatment related toxicities (except alopecia and vitiligo) less than or equal to CTCAE v5 grade 1?","url":null,"context":"NRG"},{"name":"CRF Text14","type":"Alternate Question Text","description":"has patient recovered from all toxicities?","url":null,"context":"Alliance"},{"name":"Alliance 1","type":"Alternate Question Text","description":"If yes, has patient recovered from all toxicities?","url":null,"context":"Alliance"},{"name":"NRG_CRF_Text_1","type":"Alternate Question Text","description":"Has the patient recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"NRG"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Recovery from everolimus toxicities to resolution of <= grade 1 per CTCAE v5.0.","url":null,"context":"CCTG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A5C4AB2A-4310-871F-E040-BB89AD433127","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"KUMMEROA","dateModified":"2023-04-03","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2023.3.4 Alt SN added per ticket request CADSR0002262. ak 3/8/23 added 1 AQT and 1 alt OID for CCTG ticket request CADSR0002117 cjl; 2022.12.20 AQT added for ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"}}